ASCO: Adaptimmune’s cell therapy shrinks 39% of rare sarcomas

CAR-T and other cell therapies have seen success in blood cancers but have shown limited effect in solid tumors. Adaptimmune aims to change that with an engineered T-cell receptor approach, and its first phase 2 data, from patients with rare soft-tissue sarcomas, look promising.